CONTINUED COOPERATION WITH MEDICAL
EXPERTS AND OTHER ORGANISATIONS TO INCREASE
VALUE FOR CLIENTS
The Group has been actively seeking cooperation with medical
professionals and institutions to boost the benefits for our
mother and child clients, as well as their families.
One such initiative was our recent partnership with
Dr. Michael Chez, a leading Neurologist and Director of
Pediatric Neurology and Pediatric Epilepsy at the Sutter
Medical Group and Sutter Neuroscience Institute, to embark
on an Asian study with local physicians to treat child autism
with the patient’s own cord blood. We are hopeful that cord
blood stem cells have the potential to play an imperative
role in the treatment of childhood autism, amongst other
medical conditions.
In June 2014, we were elated to learn that Duke Medicine
received a US$15 million donation from the Marcus
Foundation, to support their research to use cord blood
stem cells for autism, stroke, cerebral palsy and other
related brain disorders. We believe this initiative will
contribute to the advancement of cell therapy and
improve the lives of many. To support this programme,
the Group extended help to our valued clients so that
their applications were successfully submitted to Duke
Medicine for consideration.
1 For more details, please refer to the Circular to Shareholders dated August 26, 2015.
PEOPLE STRATEGY
Besides focusing on business operations, we acknowledge
that our employees play a significant role in driving the
growth of our business. While we have always invested in
developing our existing talent pool, an integrated talent
management framework was structured this year to formalise
our people strategy. We believe the deployment of a
comprehensive people strategy will enable the organisation
to respond to business needs more rapidly and effectively.
PROSPECTS
In the new financial year, we shall remain committed to
developing our market leadership in cord blood and cord
lining banking within the Asian region, while continuing
with our plans to introduce new healthcare products and
services that cater to the mother and child segment. The
Group is cautiously optimistic that favourable healthcare
industry trends and the strong market position of the Group
will bring us to greater heights.
Barring any unforeseen circumstances and excluding
any one-off items, the Group expects its core business to
maintain a steady growth in FY2016.
MR. JEREMY YEE PINH
Executive Director and Chief Executive Officer
14
CORDLIFE GROUP LIMITED
| ANNUAL REPORT 2015
CEO’S
MESSAGE
